Scientists at The University of Texas at El Paso have identified a potential new target in the battle against high-grade serous carcinoma, the most aggressive form of ovarian cancer.
Currently, less than 50% of women diagnosed with this type of cancer survive beyond five years.
A study published in the journal Scientific Reports highlights a protein called Claudin-4, which is found in higher amounts in ovarian cancer cells. According to the research team, Claudin-4 might be responsible for the cancer’s ability to resist treatment and avoid detection by the immune system.
The study was led by postdoctoral researcher Fabian R. Villagomez, Ph.D., of UTEP, and Benjamin G. Bitler, Ph.D., of the University of Colorado Anschutz. Using animal models with human-like immune systems, the researchers discovered that targeting Claudin-4 made tumors more vulnerable to the immune system.
Villagomez explained that cancer cells contain genetic mutations that cause them to grow aggressively. However, if these mutations are too severe, the immune system can recognize and destroy the tumor. Claudin-4 appears to help tumors adapt to these changes, allowing them to survive, evade immune detection, and avoid cell death.
The team tested a peptide known as CMP, which blocks Claudin-4, in combination with a PARP inhibitor—a drug already used in ovarian cancer treatment. Together, these therapies slowed tumor growth and enhanced the immune system’s ability to fight the cancer.
While human testing has not yet begun, Villagomez intends to continue his research on Claudin-4 and ovarian cancer. He aims to collaborate with other universities to advance the treatment and eventually bring it to patients.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
Copyright © 2025 Knowridge Science Report. All rights reserved.
